The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) decision affirming an examiner’s rejection of claims directed to oral inhalation of the drug zanamivir to treat influenza. The examiner rejected the...more
On September 8, 2016, the Federal Circuit affirmed a decision from the Eastern District of Virginia in which the district court held that UCB, Inc.’s Cimzia® antibody does not infringe Yeda’s U.S. Patent No. 6,090,923 (“the...more
DISTRICT COURT CASES -
New York Court Invalidates Targeted-Advertising Patents under Alice -
A federal judge in the Southern District of New York granted counterclaim-defendant TNS’s motion for summary judgment...more
SUPREME COURT CASES -
Post-Complaint Events or Transactions Cannot Cure Prudential Standing Defects -
The U.S. Supreme Court denied Alps South’s writ to review the Federal Circuit’s decision that the company lacked...more
2/8/2016
/ AbbVie ,
Apple ,
CLS Bank v Alice Corp ,
Inter Partes Review (IPR) Proceeding ,
Patent-Eligible Subject Matter ,
Pharmaceutical Patents ,
Prior Art ,
Royalties ,
Standing ,
Willful Infringement ,
Writ of Mandamus